Trial Profile

A Phase 1, First-in-Human, Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EVT 801 (Primary)
Indications Colon cancer; Liver cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors Kazia Therapeutics

01 Aug 2025 According to a Kazia Therapeutics media release, company announced $2 million private placement, the Company intends to use the net proceeds from this offering to support the continued clinical development of this trial.
15 May 2025 According to a Kazia Therapeutics media release, company expects final data in 2Q2025 and presenting data later this year at an international medical congress.
15 May 2025 According to a Kazia Therapeutics media release, company reached the last patient follow-up in this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com